Universal Beteiligungs und Servicegesellschaft mbH Buys 19,166 Shares of Natera, Inc. $NTRA

Universal Beteiligungs und Servicegesellschaft mbH grew its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 15.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 139,802 shares of the medical research company’s stock after purchasing an additional 19,166 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.10% of Natera worth $22,504,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hilltop National Bank bought a new position in shares of Natera in the second quarter valued at $33,000. Sound Income Strategies LLC grew its position in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 110 shares during the period. Quent Capital LLC acquired a new position in shares of Natera during the 3rd quarter worth about $46,000. V Square Quantitative Management LLC acquired a new position in shares of Natera during the 2nd quarter worth about $53,000. Finally, N.E.W. Advisory Services LLC raised its holdings in shares of Natera by 256.8% in the 2nd quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 226 shares during the period. Institutional investors own 99.90% of the company’s stock.

Natera Price Performance

NTRA stock opened at $242.91 on Friday. Natera, Inc. has a fifty-two week low of $125.38 and a fifty-two week high of $256.36. The stock has a market capitalization of $33.60 billion, a price-to-earnings ratio of -106.07 and a beta of 1.62. The business’s fifty day moving average price is $233.44 and its two-hundred day moving average price is $190.60.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter last year, the company posted ($0.26) earnings per share. The company’s revenue was up 34.7% on a year-over-year basis. Research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In related news, insider Solomon Moshkevich sold 23,205 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $5,447,141.70. Following the sale, the insider owned 144,992 shares of the company’s stock, valued at $34,035,422.08. This represents a 13.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Herm Rosenman sold 48,419 shares of the firm’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $227.42, for a total value of $11,011,448.98. Following the transaction, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. This trade represents a 70.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 514,562 shares of company stock worth $114,292,421. Insiders own 5.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on NTRA. BTIG Research boosted their price target on Natera from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Friday, December 5th. Guggenheim lifted their target price on Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. JPMorgan Chase & Co. raised their price target on Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. Finally, Evercore ISI upped their price objective on shares of Natera from $190.00 to $250.00 and gave the company an “outperform” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $245.50.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer?reviewed clinical validation of its Latitude™ tissue?free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high?value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high?profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near?term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.